QUOTE AND NEWS
Benzinga  Jan 13  Comment 
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced its key strategic objectives for 2015, details of which will be presented at the 33rd Annual J.P. Morgan Healthcare Conference on January 14, 2015 in San Francisco, California. These...
GenEng News  Dec 30  Comment 
Ariad Pharmaceuticals said today it granted Angelini Pharma exclusive rights to commercialize Iclusig® (ponatinib) in seven Central and Eastern European nations. Ariad said it will generate $7.3 million in upfront and milestone payments...
Forbes  Dec 29  Comment 
The most recent short interest data was recently released by the NASDAQ for the 12/15/2014 settlement date, and ARIAD Pharmaceuticals, Inc. (NASD: ARIA) is one of the most shorted stocks of the Russell 3000, based on 6.18 "days to cover" versus...
GenEng News  Dec 23  Comment 
Otsuka Pharmaceutical will commercialize Ariad Pharmaceuticals’ leukemia treatment Iclusig® (ponatinib) in Japan and nine other Asian countries, as well as fund future clinical trials in those countries. The deal could net Ariad as much as...
TheStreet.com  Dec 11  Comment 
NEW YORK (TheStreet) -- Shares of Ariad Pharmaceuticals are down 2.85% to $6.82 in pre-market trading after Credit Suisse downgraded the global oncology company to "underperform" from "neutral" and lowered its price target to $6 from $8....
TheStreet.com  Dec 11  Comment 
NEW YORK (TheStreet) -- RATINGS CHANGES AbbVie was downgraded at Morgan Stanley to equal-weight from overweight. Twelve-month price target is $72. Stock is already pricing in potential for Hepatitis-C and Humira, Morgan Stanley said. Alico ...




 

Ariad Pharmaceuticals develops products that use intracellular-signal-transduction pathways to treat disease. It is developing pharmaceuticals that may treat conditions such as anemia, growth-hormone deficiency, cancer, diabetes, asthma, arthritis, and osteoporosis. All of the company's products are in the research or clinical-testing stages. Ariad has not entered any partnerships for the distribution of their product candidates, preferring to have sole control of their development.





References

Morningstar.com

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki